EMA/304247/2012

European Medicines Agency decision

P/0083/2012

of 16 May 2012

on the acceptance of a modification of an agreed paediatric investigation plan for belatacept (Nulojix), (EMEA-000157-PIP01-07-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0083/2012

of 16 May 2012

on the acceptance of a modification of an agreed paediatric investigation plan for belatacept (Nulojix), (EMEA-000157-PIP01-07-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/99/2008 issued on 03 November 2008,

Having regard to the application submitted by Bristol-Myers Squibb Pharma EEIG on 20 December 2011 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 April 2012, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the waiver.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for belatacept (Nulojix), powder for concentrate for solution for infusion, intravenous use, including changes to the waiver, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, UB8 1DH Uxbridge, United Kingdom.

Done at London, 16 May 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/304247/2012

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000157-PIP01-07-M01

Scope of the application

Active substance(s):

Belatacept

Invented name:

Nulojix

Condition(s):

Prevention of rejection of transplanted kidney

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Bristol-Myers Squibb Pharma EEIG

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Bristol-Myers Squibb Pharma EEIG submitted to the European Medicines Agency on 20 December 2011 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/99/2008 issued on 3 November 2008.

The application for modification proposed changes to the agreed paediatric investigation plan and to the waiver.

The procedure started on 15 February 2012.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified. The scope of the waiver has been extended.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the waiver in the scope set out in the Annex I of this opinion.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 13 April 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Prevention of rejection of transplanted kidney

1.2. The waiver applies to:

- newborn infants (from birth to less than 28 days); infants; toddlers (from 28 days to less than 24 months) and children from 24 months to less than 6 years;
- for powder for concentrate for solution for infusion, intravenous use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric Investigation Plan

2.1. Condition: Prevention of rejection of transplanted kidney

2.1.1. Indication(s) targeted by the PIP

Prevention of acute rejection following renal transplantation.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years.

2.1.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion.

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	5	Study 1: Thirteen-week subcutaneous/intravenous toxicity study in juvenile rats
		Study 2: Three-month intermittent-dose subcutaneous and intravenous immunotoxicity study in juvenile rats
		Study 3: Three-month intermittent-dose intravenous immunotoxicity study in rats
		Study 4: In vitro evaluation of CD86 receptor occupancy in pediatric blood
		Study 5: Three-month intermittent-dose subcutaneous investigative immunotoxicity study in juvenile rats
Clinical	2	Study 6: Open-label, multi-centre, randomised, active-controlled, parallel group, multiple-dose, PK/conversion study in stable renal transplant

Area	Number of studies	Description
		recipients (from 6 to less than 18 years of age) receiving maintenance immunosuppressant therapy
		Study 7: Efficacy and safety study in de novo renal transplant recipients from 6 years to less than 18 years of age

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes.
Date of completion of the paediatric investigation plan:	By December 2023.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes.

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Prevention of rejection of transplanted kidney

   Authorised indications:

Nulojix, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant (see section 5.1 for data on renal function). It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen

EU Number	**Invented name**	**Strength**	**Pharmaceutical form**	**Route of administration**	**Packaging**	**Content (concentration)**	**Package size**
EU/1/11/694/001	Nulojix	250 mg	Powder for concentrate for solution for infusion	Intravenous use	Vial (glass); syringe (plastic)	25 mg/ml	1 vial + 1 syringe
EU/1/11/694/002	Nulojix	250 mg	Powder for concentrate for solution for infusion	Intravenous use	Vial (glass); syringe (plastic)	25 mg/ml	2 vial + 2 syringe